Novo Nordisk A/S (NOVO-B.CO)
| Previous close | 882.60 |
| Open | 890.40 |
| Bid | 883.20 x 0 |
| Ask | 883.20 x 0 |
| Day's range | 881.60 - 894.60 |
| 52-week range | 504.40 - 932.00 |
| Volume | |
| Avg. volume | 2,643,997 |
| Market cap | 3.935T |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 44.45 |
| EPS (TTM) | 19.87 |
| Earnings date | 07 Aug 2024 |
| Forward dividend & yield | 12.80 (1.45%) |
| Ex-dividend date | 22 Mar 2024 |
| 1y target est | 918.44 |
Barrons.comNovo Nordisk Sets Sights on a Long-Lasting Successor to Its Weight Loss Blockbuster
The company will collaborate with a biotech founded by Flagship Pioneering, the venture capital firm that created Moderna.
GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 8 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the
ZacksWall Street Bulls Look Optimistic About Novo Nordisk (NVO): Should You Buy?
According to the average brokerage recommendation (ABR), one should invest in Novo Nordisk (NVO). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
